Gali Arad and Eran Seger from Protai had talked to us about moving from their previous life in tech and academia into the fast pace of illuminating the druggable Proteome for better cures.Eran Seger is the Co-Founder and CEO of Protai, a fast-growing biotech startup sitting on the intersection of proteomics and machine learning to develop novel therapeutics for a variety of complex diseases. Eran is an experienced technology executive and entrepreneur with a strong technical background and over 15 years of tech leadership positions at the Israeli Intelligence forces and HighTech.Gali Arad, PhD is a Computational Biologist and the first employee of Protai, a drug discovery startup combining AI and proteomics to create intelligence-driven pharma. She is an end-to-end computational biology scientist, with broad experience in systems biology, data analysis, hands-on technological practice, and clinical samples handling. In her current role, Gali leads the scientific research, focused on target discovery and prioritization, and the collection and curation of Protai’s data warehouse. She holds a Ph.D from Tel Aviv University, applying mass-spectrometry-based proteomics to study cancer heterogeneity. Her findings were published in top-tier scientific journals and emphasized the added value of clinical proteomics in the study of cancer.

Music:Funkorama Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0 Licensehttp://creativecommons.org/licenses/by/3.0/

---

Send in a voice message: https://podcasters.spotify.com/pod/show/macademia/message